Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?

Affiliations

• ¹ Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, Faculty of Medicine of the University of Porto, Centro Hospitalar Universitário de São João, Porto, Portugal. Electronic address: jsneves@med.up.pt.
• ² Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
• ³ Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
• ⁴ Baylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
• ⁵ Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; Heart Failure Clinic, Internal Medicine Department, Unidade Local de Saúde de Gaia/Espinho, Vila Nova de Gaia, Portugal.